BSLN Share Price Performance
CHF 46.85
6.85 (17.13%)
48.2% undervalued intrinsic discount
CHF 90.42
Fair Value
Price CHF 46.85
AnalystConsensusTarget CHF 90.42
Fair ValueCHF 90.42
Share Pricen/a
Basilea Pharmaceutica AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
BSLN Community Narratives
AN
Fair Value CHF 90.42 48.2% undervalued intrinsic discount
Emerging Markets And Drug Resistance Will Drive Global Expansion
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Emerging Markets And Drug Resistance Will Drive Global Expansion
Key Takeaways Expanding global sales of key anti-infective drugs and successful commercialization partnerships are driving top-line growth and increased royalty income. Strategic pipeline development, acquisitions, and a partnership-driven model support profit growth, regulatory momentum, and future market expansion.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
CHF 90.42
48.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
9.68% p.a.
Profit Margin
23.91%
Future PE
16.39x
Share price in 2028
CHF 95.69
Snowflake Analysis
Basilea Pharmaceutica AG Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 17, 2026
- 5.91
- 46.39%
- 30.76%
- 79.5%
About BSLN
- Founded
- 2000
- Employees
- 180
- CEO
- WebsiteView website
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
